Board approval of the 2024 Financial statements for Medistim ASA

08 Apr 2025 16:18 CEST

(Oslo, 8th of April 2025) Medistim ASA (OSE: MEDI), a niche market leader
within ultrasound technology with headquarter in Norway, that develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery, announces that the Board of Medistim ASA has approved the Financial
Statements for 2024. The Financial Statements are without changes from the
preliminary Financial Statements published on the 28th of February 2025. The
annual report for 2024 is now available. The Annual General Meeting will be held
on 8th of May 2025.

About Medistim:
Medistim was established in 1984, and has a track record of profitable growth
over the past >15 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Germany, UK, Spain, Denmark,
Canada, China, Sweden and Norway, in addition to the about 60 distributors in
Europe, Asia, Middle East, Africa, and South America. For more information,
visit the Medistim home page: www.Medistim.com

This information is disclosed under Norwegian law (Verdipapirhandelloven §5-12).

For more information, contact:
President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

More information:
Access the news on Oslo Bors NewsWeb site

643235_5967007LIEEXZXJOX483_20241231_viewer_en.html
643235_5967007LIEEXZXJOX483-2024-12-31-en.zip